Navigation Links
Terumo Cardiovascular Systems Initiates U.S. Clinical Trial for Anaconda(TM) AAA Stent Graft System
Date:7/24/2009

ANN ARBOR, Mich., July 24 /PRNewswire/ -- Terumo Cardiovascular Systems (Terumo CVS) announced that it has initiated a Phase II Clinical Trial for the Anaconda(TM) AAA (Abdominal Aortic Aneurysm) Stent Graft System in the U.S. The Anaconda system is manufactured by Scotland-based Terumo subsidiary Vascutek Ltd. The first U.S. implant was performed on June 8th at Arizona Heart Hospital by the principal investigator, Julio Rodriguez-Lopez, M.D.

(Logo: http://www.newscom.com/cgi-bin/prnh/20061027/DEF004LOGO )

The objective of the Vascutek Anaconda Stent Graft System Phase II IDE Study (G030036) is to assess the safety and effectiveness of the Anaconda stent graft system in patients presenting with AAA when compared to historical open surgical repair. The Food and Drug Administration (FDA) has given Terumo CVS approval to enroll 180 patients at 20 sites, some of which will be in Canada. The primary endpoint for the study is the successful treatment of the aneurysm twelve months after the implantation of the device. Patients in the study will be followed for a total of five years.

The Anaconda system is commercially available outside the U.S. where it has been implanted in nearly 4000 patients. It received CE Mark in Europe in April 2005.

According to the Society of Vascular Surgery, physicians diagnose approximately 200,000 people with AAAs in the U.S. annually. Treatment options include medical management of co-morbidities such as hypertension or pulmonary disease, open surgical repair and endovascular repair. Endovascular repair using commercially available devices has been associated with shorter recovery times, reduced hospital stay, and other benefits.

Terumo Cardiovascular Systems Corporation manufactures and markets medical devices for the global cardiac surgery market and is the U.S. distributor for Vascutek(R) Vascular Grafts. The company is headquartered in Ann Arbor, Michigan with manufacturing operations in Ann Arbor; Elkton, Maryland; and Ashland, Massachusetts. It is one of several subsidiaries of Terumo Corporation of Japan that is focused exclusively on cardiac and vascular specialties, including Terumo Heart Inc., developer of a ventricular assist device and Vascutek Ltd., a global leader in the design and manufacture of vascular grafts. For more information, visit www.terumo-cvs.com.

Terumo Corporation is a premier global medical device company with annual sales of more than three billion dollars for the year ending March 31, 2009. Founded in 1921, the company develops, manufactures and distributes world-class medical devices for use in cardiothoracic surgery, interventional procedures, transfusion medicine, and needle and syringe products. For more information, visit www.terumo.co.jp/English/index.html.


'/>"/>
SOURCE Terumo Cardiovascular Systems
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Terumo Heart, Inc. Reaches Clinical Milestone as the 100th Patient Worldwide Receives the DuraHeart(TM) Left Ventricular Assist System
2. Terumo Heart, Inc. Reports Clinical Progress in the DuraHeart(TM) U.S. Pivotal Trial as NewYork-Presbyterian Hospital/Columbia University Medical Center Implants First Patient
3. Terumo Heart Obtains IRB Approval from the University of Michigan to Initiate DuraHeart(TM) Left Ventricular Assist System U.S. Pivotal Trial
4. Terumo Heart Summarizes Results of DuraHeart(TM) LVAS Implants
5. Terumo Heart Reports Summary of DuraHeart(TM) LVAS Clinical Trial Results
6. Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in September
7. VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease
8. Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009
9. Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk
10. Large, Long-Term Study Shows Avandia Has No Increased Overall Cardiovascular Risk Compared to Other Commonly Used Diabetes Medicines
11. CardioVascularCS.Org, a division of EndoVascular Forum, Inc., Partners with Complex Interventional Cardiovascular Therapy (CICT) to Extend Electronic Medical Care Advancement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... , January 16, 2017 Bill is ... number of general management and leadership positions with global medical device ... a strong track record of launching new products and building successful ... , Africa and North ... ...
(Date:1/16/2017)... -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) is pleased to announce ... to its Board of Directors. He is the President ... LLC . He is also the Chief Investment Officer ... firm with over $1.5 billion under management. ... analysis and portfolio management. He began his career in ...
(Date:1/15/2017)... , Jan. 14, 2017 ImmersiveTouch Inc., ... for surgeons, today announced recent appointments strengthening their Executive ... James Bowman as Chief Executive Officer, Jay ... as Vice President of Sales and Jia ... Mr. Bowman has 20 ...
Breaking Medicine Technology:
(Date:1/15/2017)... ... 2017 , ... The JPR Group, a public relations and ... will be assisting HackensackUMC Mountainside with its public relations efforts, effective January 2017. ... towns. The firm will be working closely with HackensackUMC Mountainside’s internal marketing operations. ...
(Date:1/14/2017)... ... January 14, 2017 , ... AgileMinder develops innovative products ... The Emoji Scale is now available on Apple as a fun, free emoji sticker ... by choosing one of the ten color coded values on The Emoji Scale. ...
(Date:1/13/2017)... Madrid, Spain (PRWEB) , ... January 13, 2017 , ... ... the Melia Avenida America hotel on March 3-4, 2017. This Congress is expertly ... focused on the management of patients with lung cancer. , Chaired by Dr. Giorgio ...
(Date:1/13/2017)... ... January 13, 2017 , ... ... has taken on the challenge of providing additional organic alternatives for customers who ... launch of the brand’s new line of all-natural activated charcoal products, Moody Zook ...
(Date:1/13/2017)... ... , ... People who have sensitive teeth are about as common as those ... Sadly, most dental hygiene products in the market contain chemical ingredients that only aggravate ... their daily oral care routine to keep their teeth white and healthy is a ...
Breaking Medicine News(10 mins):